All the news Showing 10 of 119 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Over 300,000 people waiting for hepatitis C treatment in the United States Keith Alcorn / 20 June 2018 At least 300,000 people were awaiting treatment for hepatitis C by the end of 2016 in the United States, with the lowest rates of treatment observed in the Upper Midwest, ... Fatty liver improves rapidly after hepatitis C cure Michael Carter / 18 June 2018 Liver stiffness and liver fat (steatosis) in people with chronic hepatitis C virus (HCV) infection both improve significantly after treatment with direct-acting antivirals (DAAs) resulting in sustained virological response (SVR), ... Does portal hypertension always improve after hepatitis C cure? Keith Alcorn / 10 May 2018 Although portal hypertension improves in the majority of people with hepatitis C and cirrhosis after hepatitis C is cured, not all people experience improvement, and oesophageal varices may continue to ... Fewer non-liver cancers in people treated with DAAs compared to the interferon era Keith Alcorn / 02 May 2018 The risk of non-liver cancer is lower in people treated with direct-acting antivirals (DAAs) than in those treated with interferon and is probably an effect of the improved cure rate ... Curing hepatitis C reduces deaths and liver disease Keith Alcorn / 17 April 2018 Curing hepatitis C infection significantly reduces deaths from liver disease and reduces the incidence of decompensation, two large prospective studies from Italy and Scotland show. The findings were presented on ... Australian experience shows that use of DAAs can virtually eliminate HCV among prisoners Michael Carter / 19 March 2018 Hepatitis C virus (HCV) infection can be rapidly eliminated in prison populations with the use of direct-acting antivirals (DAAs), results of an Australian study published in Clinical Infectious Diseases suggests. ... Curing hepatitis C with DAAs linked to 71% reduction in liver cancer Liz Highleyman / 30 October 2017 People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, ... Maviret cures most people with HCV genotype 3 and those with cirrhosis Liz Highleyman / 24 October 2017 Glecaprevir and pibrentasvir, the two drugs in the recently approved Maviret co-formulation, demonstrated high sustained response rates for people with chronic hepatitis C virus (HCV) genotype 3 and for people with liver ... Hepatitis C cure leads to improved quality of life Liz Highleyman / 23 October 2017 People who were cured of hepatitis C with direct-acting antivirals (DAAs) had sustained improvements in their health-related quality of life, including both physical and mental health measures, according to study ... Restrictions on free DAA access in many European countries contrary to guidelines and undermine HCV elimination targets, say researchers Michael Carter / 16 October 2017 The restrictions which many European countries impose on free/reimbursed access to hepatitis C virus (HCV) direct-acting antivirals (DAAs) are contrary to guidelines and undermine the World Health Organization (WHO) goal ... ← Prev12345...12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive